Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CABAZITAXEL FOR SYSTEM SUITABILITY CRS (10 MG)

CABAZITAXEL FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
TETRACOSACTIDE FOR PEAK IDENTIFICATION CRS (0.206 MG)

TETRACOSACTIDE FOR PEAK IDENTIFICATION CRS (0.206 MG)

ND

DISCOVER
MORPHINE HYDROCHLORIDE TRIHYDRATE - REFERENCE SPECTRUM (N/A)

MORPHINE HYDROCHLORIDE TRIHYDRATE - REFERENCE SPECTRUM (N/A)

ND

DISCOVER
ERLOTINIB HYDROCHLORIDE CRS (150 MG)

ERLOTINIB HYDROCHLORIDE CRS (150 MG)

ND

DISCOVER
ERLOTINIB IMPURITY MIXTURE CRS (0.002 MG)

ERLOTINIB IMPURITY MIXTURE CRS (0.002 MG)

ND

DISCOVER
URSODOXICOLTAURINE IMPURITY ACRS (25 MG)

URSODOXICOLTAURINE IMPURITY ACRS (25 MG)

ND

DISCOVER
BROMPERIDOL FOR SYSTEM SUITABILITY CRS (0.74 MG)

BROMPERIDOL FOR SYSTEM SUITABILITY CRS (0.74 MG)

ND

DISCOVER
CHLOROQUINE PHOSPHATE FOR PEAK IDENTIFICATION CRS (15 MG)

CHLOROQUINE PHOSPHATE FOR PEAK IDENTIFICATION CRS (15 MG)

ND

DISCOVER
URSODOXICOLTAURINE FOR IMPURITY B IDENTIFICATION CRS (10 MG)

URSODOXICOLTAURINE FOR IMPURITY B IDENTIFICATION CRS (10 MG)

ND

DISCOVER
CIPROFIBRATE FOR SYSTEM SUITABILITY B CRS (2.03 MG)

CIPROFIBRATE FOR SYSTEM SUITABILITY B CRS (2.03 MG)

ND

DISCOVER
CHLOROQUINE PHOSPHATE IMPURITY C CRS (15 MG)

CHLOROQUINE PHOSPHATE IMPURITY C CRS (15 MG)

ND

DISCOVER
MERCAPTOPURINE MONOHYDRATE CRS (15 MG)

MERCAPTOPURINE MONOHYDRATE CRS (15 MG)

ND

DISCOVER